Nasdaq

Disc Medicine Highlights Positive Clinical Data for Bitopertin, DISC-0974, and DISC-3405 at EHA 2025; Management to Host Corporate Update Call

Disc Medicine announces positive updates on bitopertin, DISC-0974, and DISC-3405, with plans for upcoming clinical trials and data presentations. Disc Medicine, Inc. recently provided positive updates ...
Seeking Alpha

Disc Medicine Announces Receipt of FDA Commissioner’s National Priority Voucher (CNPV) for Bitopertin in Erythropoietic Protoporphyria (EPP)

Disc is seeking accelerated approval of bitopertin for patients aged 12 years and older with EPP The CNPV program is designed to reduce the drug application review process to 1-2 months WATERTOWN, ...